Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge

Given that robust immune responses were obtained from a highly attenuated SIVmegalo infection, an initial homologous challenge study was per- formed on two animals (macaques 93029

In contrast, anamnestic antibody responses were undetectable in the protected vaccinees within the first 4 weeks postchallenge (Fig. 4A), and titers remained below the limit

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following

Infectious viral burdens in cats vaccinated with inactivated virus and adjuvant controls measured at 6, 12, and 18 weeks postchallenge by quantitative virus isolation.. The

Concomitant with an increase in viral load, a recombinant of the vaccine virus and the challenge virus ap- peared in those two vaccinated monkeys, which had the highest viral load

After pathogenic virus challenge, monkeys immunized with the partially attenuated virus had 100- to 1,000-fold-lower viral load in peripheral blood mononuclear cells and lymph

Summary of response categories for macaques immunized with SIVmac251BK28 vaccines, using the criteria of cumulative frequency of virus isolation from PBMC, provirus burden in PBMC

There were no significant differences in vaccine strain viral loads among the animals that became infected versus those that remained uninfected after intravenous challenge with SIV